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INTRODUCTION
Brucellosis is one of the world’s most widespread
zoonoses; the disease is common in areas where
domestic animals harboring Brucella spp. are
raised, where adequate control measures are lacking
and where the population has the custom of ingest-
ing unpastorized milk or its products. In Sicily, the
largest Italian island, brucellosis is highly endemic
and has shown a marked resurgence in the last few
years (14 cases per 100,000) 1. However, fewer
than 200 total cases per year (0.04 cases per
100,000 population) are reported in the United
States 2.
Brucella spp. are intracellular pathogens that
can survive and multiply within mononuclear phago-
cytes (monocytes and macrophages) of the reticulo-
endothelial system (RES). Localization within organs
of RES may explain some of the clinical manifesta-
t ions of systemic brucel losis, such as
hepatosplenomegaly and the propensity for involve-
ment of the skeletal system 3. Lack of diagnosis or
effective treatment may result in serious and some-
times life-threatening complications such as spondyli-
tis, endocarditis and encephalitis.
Brucellae are sensitive in vitro to a number of
antibiotics; however, clinical efficacy does not always
correlate with in vitro susceptibility. Tetracycline
compounds remain the most effective antibiotics for
treating brucellosis. The treatment of choice for
acute brucellosis is considered a 6-week regimen of
tetracycline administered orally in combination with
streptomycin (1 g/day intramuscularly for 2-3 weeks)
3. Although other antibiotics have been used, no
substantial improvement in relapse rates has been
reported in association with any new treatment regi-
men in the past 45 years 4. In 1986 the World
Health Organization (WHO) recommended therapy
with the combination of doxycycline (200 mg/day)
plus rifampin (600-900 mg/day) both administered
once daily by mouth for 6 weeks 5. However, a
recent randomized controlled trial involving 194
adult patients indicated that treatment with a
rifampin/doxycycline combination was associated
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Summary
In order to evaluate the efficacy and tolerability of a high intravenous dose of
rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of
acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive
patients (135 adults and 104 children) diagnosed and treated over a 17-year peri-
od in Italy. The combination used resulted in 100% response and a relapse rate
lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild
adverse effects including an increase in aspartate aminotransferase (>250 IU)
observed in 12 cases and considered related to rifampin and in 11 cases a
reversible hyperpigmentation of the tongue attributed to minocycline. A randomized
prospective comparative study should be performed to confirm our encouraging
results. 


































TREATMENT OF HUMAN BRUCELLOSIS WITH RIFAMPIN PLUS MINOCYCLINE 249
with more relapses than that of a streptomycin/
tetracycline combination (16% and 5.3%, respective-
ly) 6. Experience with different treatments in child-
hood brucellosis is sparse 7-9 and generally tetracy-
clines are not used in children ≤8 years of age. 
Since 1984 we have principally used the combi-
nation of intravenous rifampin (10 mg/Kg, max 600
mg) and oral minocycline (children 2.5 mg/Kg, max
100) twice a day for 3 weeks for the treatment of
brucellosis both for adults and children (also <8
years). We preferred minocycline to doxycycline
because of its higher liposolubility and better tissue
penetration, as well as its superior oral bioavailabili-
ty; furthermore the drug shows higher splenic and
liver levels and is also active (not chelated) in the
bone tissue. Minocycline also chelates calcium less
than other tetracyclines and so it is theoretically less
likely to cause tooth staining (due to the deposition
of tetracycline/orthophosphate complexes) 10. Half
of each dose of rifampin was administered by means
of parenteral route in 15 minutes, the other half in
2 hours, in order to achieve higher blood levels for a
longer period afterward, approaching the kinetic
profiles and improving the theoretical synergistic
effect of rifampin and minocycline - each antibiotic
acts on protein synthesis with a different mechanism
(rifampin inhibits the mRNA synthetase, tetracyclines
block the 30S subunit of the ribosome) 11.
In this study we have retrospectively reviewed
the characteristic of 239 consecutive patients with
brucellosis identified over a 17-year period to evalu-
ate the efficacy and safety of this new scheme of
therapy.
PATIENTS AND METHODS
The “G. Di Cristina” Hospital in Palermo is the
largest children’s hospital in Sicily. It is a tertiary-
care university hospital with 350 beds serving a
population of about 1,000,000 in the Palermo dis-
trict and, in addition, the hospital serves as referral
pediatric hospital for all of western Sicily. The infec-
tious diseases department has 40 beds for inpatient
children and 5 beds both for adult and children out-
patients.
All patients with brucellosis consecutively diag-
nosed from March 1984 through December 2000
were included in this review. A patient was consid-
ered to have brucellosis if he met at least 2 of the
following criteria: 1) isolation of Brucella spp. from
blood or other fluids or tissue; 2) finding of a
≥1:160 standard tube agglutination titer of antibod-
ies to Brucella spp.; 3) presence of clinical signs
compatible with brucellosis (fever, sweats, arthral-
gias, hepatomegaly, splenomegaly, and/or signs of
focal disease). Fever was defined as a axillary tem-
perature ≥38.0°C. Standard tube agglutination test-
ing, the Rose-Bengal test, and the Coombs test for
antibodies to Brucella species were done according
to standard methods with commercial reagents. 
Diagnosis of spondylitis or arthritis was made on
the basis of physical examination and with use of
radiological or magnetic resonance imaging studies.
The treatment schedule consisted of the adminis-
tration of intravenous rifampin (Rifadin Lepetit)
(children 10 mg/Kg, max 600 mg) and oral minocy-
cline (Minocin Lederle) (children 2.5 mg/Kg, max
100 mg) twice daily for 3 weeks. Each dose of
rifampin was diluted in 250 ml of 5% glucose solu-
tion, half of which was administered intravenously in
15 minutes and the other half in 2 hours. For some
patients with focal disease the same treatment was
prolonged for 6 weeks with rifampin given orally in
the last 3 weeks. 
Other schedules were based on the physician’s
preference or if the patient was not able to come to
hospital every day for the intravenous treatment. 
Clinical response was assessed at the end of
treatment and was defined as cure (defervescence,
restoration of laboratory parameters, or reduction of
spleen size and disappearance of symptoms) or fail-
ure (persistent or worsening clinical and laboratory
findings). Relapse was defined by the reappearance
of symptoms or signs of the disease or by new posi-
tive blood culture after therapy.
Most of the patients were monitored for thera-
peutic efficacy and signs of drug toxicity through
obtainment of the following clinical data: determina-
tion of blood cell counts and erythrocyte sedimenta-
tion rates, urinalysis, measurements of the creati-
nine, aspartate aminotransferase, alkaline phos-
phatase, bilirubin and electrolyte levels, Brucella
serology and blood culture.
Following therapy, most patients were re-exam-
ined on an outpatient basis at regular 3-month inter-
vals for 18 months as well as whenever clinical
symptoms reappeared. While preparing this article,
whenever feasible, we contacted patients or their
parents by telephone to gather further follow-up
data. Informed consent was obtained from the
patients or from their parents and the guidelines of
the G. Di Cristina Hospital were followed in the
conduct of the clinical research.
RESULTS
From March 1984 to December 2000, 239
consecutive patients (135 adults and 94 children)
were diagnosed with brucellosis and 174 treated
with the above protocol. Admissions were evenly
distributed throughout the years studied. All patients
were HIV-negative. In all cases the disease was con-
tracted in western Sicily, in 39 cases (9 clusters)
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was due to the ingestion of the same dairy products.
The characteristics of the patients are summarized in
Table 1. 
All the children were admitted as inpatients and
stayed in hospital during the treatment period; all
the adults were treated as outpatients and 80 of
them came to hospital twice daily for the treatment.
Therapeutic failure was not observed in any of
the patients. Among the 174 patients treated with
our scheme, 3 cases (2 children +1 adult) (1.7%)
relapsed while 10 of the 65 (15.3 %) patients treat-
ed with other protocols did. Twelve of the 13
patients experiencing relapses were treated with a 3-
week course of rifampin-minocycline, the remaining
patient with a streptomycin/doxycycline combina-
tion; all these patients recovered without any sequel
(Table 2).
The mean time to defervescence was 3.5 days
(range, 1 - 6 days) in the 174 patients treated with
our scheme. Fifty-two (30 adults and 22 children)
(29.8%) experienced one or more adverse effects
during therapy: epigastric discomfort in 36 cases;
nausea in 28; diarrhea in 8, vomiting in 3, dizziness
in 22; phlebitis at the infusion site in 6. In 12
patients a mild erythematous rash and asthenia
occurred after the first administrations of rifampin.
These reactions were classified as grade (I-II) accord-
ing to WHO and did not require any discontinuation
of the treatment. In 12 patients a marked increase
of aspartate aminotransferase (>250 IU) was noted
after the first week, and in 6 after the second week;
these changes were considered to be related to
rifampin; in 11 cases its administration was inter-
rupted for a week, in four cases rifampin was
replaced with streptomycin. No patients complained
of teeth discoloration. Hyperpigmentation of the
tongue was observed in 6 children and 5 adults and
resolved spontaneously 2 weeks after discontinuation
of therapy.
The median follow-up was 9 months (range, 3-
18 months). Two hundred nine patients (87.4%)
were followed up for at least 6 months. Five patients
were lost to follow up; 40 patients were contacted
by telephone interview. 
DISCUSSION
One of the major concerns regarding the treat-
ment of brucellosis is the high rate of relapse, rang-
ing from 5% to 17% when employing either the
combination of streptomycin plus doxycycline or
rifampin plus doxycycline. The latter is endorsed by
the WHO 6.
In a recent study the rifampin minimal inhibitory
concentrations (MICS) for 50% and 90% of 86 iso-
lates of B. melitensis were 2.5 mg/L and 4.0 mg/L
respectively and rifampin has been found to be bac-
tericidal for Brucella at a concentration of 4x the
MIC between 24 and 48 hours 12. Rifampin concen-
trates in phagocytic cells 13-14, and its activity is
increased 2- to 8-fold at pH 5.0 15, the pH of the
TABLE 1 - Baseline characteristics of the 239 patients with brucellosis.
Variables Adults Children
n=135 n=104
Median age (years) (range) 37 (15-86) 7 (1-14)
N. of males (%) 73 (54 %) 54 (51.9 %)
N. (%) with risk factor for brucellosis
Occupational exposure 28 (25.9 %)
Ingestion of unpasteurized dairy products 70 (51.8 %) 73 (70.1 %)
Duration of symptoms before therapy: median n° of days (range) 30 (4-360) 15 (4-180)
Median AST UI/L (range) 34 (8 -388) 58 (18-498)
N. with AST >100 IU (%) 17 (12.5) 29 (27.8)
Median agglutination titer (range) 320 (20 - 5,120) 908.5 (40-10,240)
N. with focal disease
Spondylitis 2





*A 23-year old women, in which B. melitensis was cultured from the fluid present in the pouch of Douglas. She
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phagolysosome of macrophages in which Brucella
spp. grows and replicates 16.
After an intravenous dose of 600 mg the Cmax of
rifampin is 15 mg/L, while after an oral dose of
900 mg the Cmax of rifampin (after 3 hours) is 12
mg/L. The amount of free rifampin, unbound to
plasma proteins (e.g. the active fraction), is on aver-
age 17.5% (range, 10-25%) so it will be theoretical-
ly 2.6 mg/L and 2 mg/L respectively for the i.v.
600 mg and for the orally administered 900 mg.
The latter value is below the MIC50 value. The mean
half-life is 4 hours (range, 2-6 hours) 17. With a sec-
ond i.v. 600 mg dose after 12 h we should guaran-
tee concentrations higher than the MIC of 2.5 mg/L
for at least 8 hours. 
In the previously cited study 12 minocycline was
the most active antibiotic in vitro against B.
melitensis showing the lowest MIC among all the
other conventional anti-brucella antibiotics (strepto-
mycin, cotrimoxazole, rifampin). After a single oral
dose of 200 mg the Cmax of minocycline is 4 mg/L
and that of doxycycline 3.5 mg/L, then the drug
concentration decreases with a half-life of 16 hours
for minocycline and 18 hours for doxycycline, but
the amount unbound to plasma proteins (e.g. the
active fraction) is on average 32% for minocycline
and only 12.5% for doxycycline, so the free minocy-
cline is theoretically more than double the free doxy-
cycline 18.
Based on the above reported pharmacokinetic
considerations, we adopted a different regimen; the
dose of rifampin was higher than generally recom-
mended and the intravenous route of administration
allowed a more favorable kinetic profile against bru-
cellae. 
Favorable results employing minocycline alone or
in combination with rifampin for the therapy of bru-
cellosis have been previously reported by Italian
researchers during the mid-eighties (relapse rate of
3.4 –4%) 4.
The results of our retrospective study show that
the combination of intravenous rifampin plus oral
minocycline administered for 3 weeks obtained the
lowest relapse rate (1.7%) so far reported for treat-
ment of human brucellosis. In fact, in a randomized
controlled trial comparing the combination therapy
endorsed by WHO i.e. (doxycycline plus rifampin)
versus streptomycin plus doxycycline, the relapse
rates were 16% and 5.3%, respectively 6; other
studies did not report better results 3-5,19.
The likely explanation of this impressive success
is probably due to the higher dose of rifampin used
and the parental route of administration coupled
with a therapeutic profile of minocycline that is pos-
sibly better than that of doxycycline. However, these
assertions are speculative and largely unproved since
no pharmacokinetic study was performed in our
patients.
The most frequently observed adverse effects
were dizziness and gastrointestinal symptoms, both
considered to be related to minocycline.
Reports of minocycline-induced hyperpigmenta-
TABLE 2 - Treatment * and outcome of the 239 patients with brucellosis.
N. Focal disease Cure Relapse Adverse effects
Adults
Rifampin i.v. + minocycline x 21d 80 4 80/80 1/80 30/80
Rifampin i.v. x 7d followed by rifampin 19 0 19/19 3/19 4/19
p.o. x 14 d + minocycline x 21d
Rifampin p.o. + minocycline x 21d 11 0 11/11 2/11 3/11
Rifampin i.v. + minocycline x 21d followed 13 4 13/13 0/13 12/13
by rifampin p.o. + minocycline x 21d (total 42 d)
Other treatment** 12 0 12/12 5/12 4/12
Children
Rifampin i.v. + minocycline x 21d 94 1 94/94 2/94 22/94
Other treatment§ 10 2 10/10 0/10 3/10
*In all cases rifampin was dosed at 10 mg/Kg (max 600 mg) twice daily. **Nine cases received: rifampin alone or com-
bination of rifampin with ofloxacin or with doxycycline, or streptomycin + doxycycline, or minocycline + pefloxacin, in all
the cases x 21 d; 3 cases received rifampin i.v. + doxycycline x 21d followed by rifampin p.o. + doxycycline x 21d (total
42 days). §Six cases were administered rifampin i.v. + doxycycline x 21d; 1 case rifampin i.v. + doxycycline + chloram-
phenicol x 21d; 1 case streptomycin + doxycycline x 21 days, 1 case rifampin p.o. + minocycline x 21 d; 1 case rifampin
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tion affecting the oral mucous membranes are rare.
Although minocycline is the only tetracycline associ-
ated with oral mucosal pigmentation, its cause
remains unknown. It has been suggested that either
a minocycline-metabolite complex or melanin, iron
and calcium-containing granules are the source of
the pigment. Oral pigmentation develops at sites
predisposed to oral trauma such as the tongue. The
pigmentation appears to be unrelated to the dura-
tion of minocycline therapy or the cumulative dose,
and resolves completely when the drug is discontin-
ued 20. 
However, several issues should be considered in
interpreting the results of this study: first, the retro-
spective nature of the study and the absence of a
predefined clinical end-point are recognized as a
source of potential bias; second, the higher dose of
rifampin used might be responsible for an increase
in adverse effects; however the overall percentage of
adverse effects was similar to that reported with
standard regimens 5; furthermore the parental route
of administration of rifampin requiring prolonged
hospitalization may be considered unfeasible in most
institutions due to the cost and inconvenience to the
patient. These considerations must be weighed with
the cost of retreatment in case of relapse and the
possible severe and unresponsiveness to therapy of
organ complications. The last issue regards the use
of tetracycline in children under 8 years of age, but
doxycycline is recommended by the American
Academy of Pediatrics for the treatment of Rocky
Mountain spotted fever at any age 21. However, no
patients complained of teeth discoloration at the end
of follow-up, and it is not mentioned in the works of
other authors who used minocycline in children 11,22,
suggesting the possibility of using this antibiotic for a
short period among pediatric patients.
In conclusion, we believe that, based on our
results, even if the WHO recognizes doxycycline and
oral rifampin as the standard therapy of brucellosis,
it would be interesting to perform a randomized,
prospective, comparative study to confirm the excel-
lent results obtained with the schedule used in our
study.
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